New perspectives and new ideas
Biotech company Genmab creates and develops therapeutic antibodies for the treatment of different types of cancer. It is an international company, with its Research and Development Center in Utrecht, in a brand new building next to the Hubrecht Institute. Janine Schuurman explains Genmab's choice for Utrecht.
More to it than mere history
Genmab is internationally active, with a strong focus on the US and European markets. The company is also a partner in the, rather local, Molecular Immunology Hub. Why are there such strong ties with Utrecht? "We have strong and long-standing partnerships with multiple research groups at both the university and the university medical center", says Janine Schuurman, Corporate Vice President Research and Innovation at Genmab. "Our company is international, and there is a substantial Dutch contribution to its history and its foundation. Our CEO, Jan van de Winkel, who co-founded Genmab, holds a professorship of Immunotherapy at Utrecht University and we have been located here at the campus since the company was founded in 1999. " But there has to be more to it than mere history? "Of course there is. The main reason we chose to create our new Research & Development Center here and to join the Hub is the overall high level and broad scope of immunology research of the Utrecht-based groups, institutes and companies. From basic research into structure-function relationships to translational research at the UMC Utrecht, it is all here."